The Experts below are selected from a list of 14850 Experts worldwide ranked by ideXlab platform
B M Mercer - One of the best experts on this subject based on the ideXlab platform.
-
magnesium sulfate therapy in preeclampsia is associated with increased urinary Cyclic Guanosine Monophosphate excretion
American Journal of Obstetrics and Gynecology, 1992Co-Authors: J R Barton, B M Sibai, R A Ahokas, David W Whybrew, B M MercerAbstract:Abastract OBJECTIVE: Our objective was to determine if maternal urinary Cyclic Guanosine Monophosphate levelsare altered in preeclampsia. STUDY DESIGN : Aliquots from 24-hour urine samples collected from 57 women with preeclampsia and 14 normotensive pregnant women in the third trimester of pregnancy were assayed for urinary Cyclic Guanosine Monophosphate. Urinary Cyclic Guanosine Monophosphate values were expressed per milligram of urinary creatinine to standardize for renal function. RESULTS : There was no difference in gestational age at time of urine collection between the two groups. Urinary Cyclic Guanosine Monophosphate levels (mean ± SD) were similar between normotensive and preeclamptic pregnant women (751 ± 498 vs 632 ± 363 pmol/mg urinary creatinine, respectively, p = 0.12). Preeclamptic women receiving magnesium sulfate had significantly higher levels of urinary Cyclic Guanosine Monophosphate than those not receiving magnesium sulfate (786 ± 360 vs 555 ± 344 pmol/mg urinary creatinine, respectively, p = 0.02). CONCLUSIONS : These preliminary results indicated that Cyclic Guanosine Monophosphate excretion increases in patients with preeclampsia during magnesium sulfate infusion. The vascular smooth muscle relaxation effects of magnesium sulfate may be mediated by directly increasing Cyclic Guanosine Monophosphate production or indirectly through endothelium-derived relaxing factor. (Am J Obstet Gynecol 1992;167:931–4.)
-
Magnesium sulfate therapy in preeclampsia is associated with increased urinary Cyclic Guanosine Monophosphate excretion.
American journal of obstetrics and gynecology, 1992Co-Authors: J R Barton, B M Sibai, R A Ahokas, W D Whybrew, B M MercerAbstract:Our objective was to determine if maternal urinary Cyclic Guanosine Monophosphate levels are altered in preeclampsia. Aliquots from 24-hour urine samples collected from 57 women with preeclampsia and 14 normotensive pregnant women in the third trimester of pregnancy were assayed for urinary Cyclic Guanosine Monophosphate. Urinary Cyclic Guanosine Monophosphate values were expressed per milligram of urinary creatinine to standardize for renal function. There was no difference in gestational age at time of urine collection between the two groups. Urinary Cyclic Guanosine Monophosphate levels (mean +/- SD) were similar between normotensive and preeclamptic pregnant women (751 +/- 498 vs 632 +/- 363 pmol/mg urinary creatinine, respectively, p = 0.12). Preeclamptic women receiving magnesium sulfate had significantly higher levels of urinary Cyclic Guanosine Monophosphate than those not receiving magnesium sulfate (786 +/- 360 vs 555 +/- 344 pmol/mg urinary creatinine, respectively, p = 0.02). These preliminary results indicated that Cyclic Guanosine Monophosphate excretion increases in patients with preeclampsia during magnesium sulfate infusion. The vascular smooth muscle relaxation effects of magnesium sulfate may be mediated by directly increasing Cyclic Guanosine Monophosphate production or indirectly through endothelium-derived relaxing factor.
J R Barton - One of the best experts on this subject based on the ideXlab platform.
-
magnesium sulfate therapy in preeclampsia is associated with increased urinary Cyclic Guanosine Monophosphate excretion
American Journal of Obstetrics and Gynecology, 1992Co-Authors: J R Barton, B M Sibai, R A Ahokas, David W Whybrew, B M MercerAbstract:Abastract OBJECTIVE: Our objective was to determine if maternal urinary Cyclic Guanosine Monophosphate levelsare altered in preeclampsia. STUDY DESIGN : Aliquots from 24-hour urine samples collected from 57 women with preeclampsia and 14 normotensive pregnant women in the third trimester of pregnancy were assayed for urinary Cyclic Guanosine Monophosphate. Urinary Cyclic Guanosine Monophosphate values were expressed per milligram of urinary creatinine to standardize for renal function. RESULTS : There was no difference in gestational age at time of urine collection between the two groups. Urinary Cyclic Guanosine Monophosphate levels (mean ± SD) were similar between normotensive and preeclamptic pregnant women (751 ± 498 vs 632 ± 363 pmol/mg urinary creatinine, respectively, p = 0.12). Preeclamptic women receiving magnesium sulfate had significantly higher levels of urinary Cyclic Guanosine Monophosphate than those not receiving magnesium sulfate (786 ± 360 vs 555 ± 344 pmol/mg urinary creatinine, respectively, p = 0.02). CONCLUSIONS : These preliminary results indicated that Cyclic Guanosine Monophosphate excretion increases in patients with preeclampsia during magnesium sulfate infusion. The vascular smooth muscle relaxation effects of magnesium sulfate may be mediated by directly increasing Cyclic Guanosine Monophosphate production or indirectly through endothelium-derived relaxing factor. (Am J Obstet Gynecol 1992;167:931–4.)
-
Magnesium sulfate therapy in preeclampsia is associated with increased urinary Cyclic Guanosine Monophosphate excretion.
American journal of obstetrics and gynecology, 1992Co-Authors: J R Barton, B M Sibai, R A Ahokas, W D Whybrew, B M MercerAbstract:Our objective was to determine if maternal urinary Cyclic Guanosine Monophosphate levels are altered in preeclampsia. Aliquots from 24-hour urine samples collected from 57 women with preeclampsia and 14 normotensive pregnant women in the third trimester of pregnancy were assayed for urinary Cyclic Guanosine Monophosphate. Urinary Cyclic Guanosine Monophosphate values were expressed per milligram of urinary creatinine to standardize for renal function. There was no difference in gestational age at time of urine collection between the two groups. Urinary Cyclic Guanosine Monophosphate levels (mean +/- SD) were similar between normotensive and preeclamptic pregnant women (751 +/- 498 vs 632 +/- 363 pmol/mg urinary creatinine, respectively, p = 0.12). Preeclamptic women receiving magnesium sulfate had significantly higher levels of urinary Cyclic Guanosine Monophosphate than those not receiving magnesium sulfate (786 +/- 360 vs 555 +/- 344 pmol/mg urinary creatinine, respectively, p = 0.02). These preliminary results indicated that Cyclic Guanosine Monophosphate excretion increases in patients with preeclampsia during magnesium sulfate infusion. The vascular smooth muscle relaxation effects of magnesium sulfate may be mediated by directly increasing Cyclic Guanosine Monophosphate production or indirectly through endothelium-derived relaxing factor.
R E Garfield - One of the best experts on this subject based on the ideXlab platform.
-
Involvement of a nitric oxide-Cyclic Guanosine Monophosphate pathway in control of human uterine contractility during pregnancy.
American journal of obstetrics and gynecology, 1995Co-Authors: Irina A. Buhimschi, C Yallampalli, Yuan-lin Dong, R E GarfieldAbstract:Abstract OBJECTIVES: The aims of the study were to investigate whether a nitric oxide-Cyclic Guanosine Monophosphate relaxation pathway is present in the human uterus and whether it differentially inhibits contractility during pregnancy and labor. STUDY DESIGN: Myometrial strips were obtained from pregnant women who were either in labor or not in labor and from nonpregnant women. Nitrites and Cyclic Guanosine Monophosphate production by the tissues and contractile responses to nitric oxide modifiers were measured. RESULTS: Biochemical assays revealed that nitric oxide (nitrites) and Cyclic Guanosine Monophosphate are generated by the human uterus. Cyclic Guanosine Monophosphate production by the uterus was increased by l-arginine (the substrate for nitric oxide) and diethylamine/nitric oxide (a nitric oxide donor) and decreased by nitro-l-arginine methyl ester (an inhibitor of nitric oxide synthase). Spontaneous contractility in vitro was increased by nitro-l-arginine methyl ester and decreased by diethylamine/nitric oxide, which furthermore produced a dose-dependent inhibition of contractility, and the median effective dose of inhibition in tissues from nonlaboring pregnant patients (1.5 ± 0.4 μmol/L) is substantially lower than in tissues from laboring pregnant (21.7 ± 7.4 μmol/L or nonpregnant (20.8 ± 4.4 μmol/L) women. These studies show that the nitric oxide-Cyclic quanosine Monophosphate system exists in the human uterus and that it inhibits contractility. Furthermore, the relaxation responsiveness to nitric oxide is elevated during pregnancy and decreased during labor. CONCLUSION: A nitric oxide-Cyclic Guanosine Monophosphate relaxation pathway is present in the human uterus and may be responsible for maintaining uterine quiescence during pregnancy. A decrease in uterine relaxation responsiveness to nitric oxide at term may play a role in the initiation of labor.
-
An L-arginine-nitric oxide-Cyclic Guanosine Monophosphate system exists in the uterus and inhibits contractility during pregnancy.
American journal of obstetrics and gynecology, 1994Co-Authors: C Yallampalli, H Izumi, M Byam-smith, R E GarfieldAbstract:Nitric oxide is synthesized from L-arginine and it causes relaxation of smooth muscle by elevating Cyclic Guanosine Monophosphate levels. We hypothesized that an L-arginine-nitric oxide-cGMP system is present in the uterus and modulates contractility. Isometric tension of the uterus was measured in vitro from pregnant rats in response to various agents that modulate nitric oxide-Cyclic Guanosine Monophosphate production or action. Major findings are as follows: (1) The substrate and a donor of nitric oxide produced uterine relaxation; (2) inhibitors of the nitric oxide-Cyclic Guanosine Monophosphate pathway blocked the relaxation responses; (3) nitric oxide synthase was localized to several uterine cell types; (4) nitric oxide was produced by the uterus during periods when L-arginine was consumed and citrulline levels increased; (5) effects of nitric oxide substrate on relaxation were mimicked by Cyclic Guanosine Monophosphate; (6) nitric oxide-Cyclic Guanosine Monophosphate responses were decreased during delivery; (7) L-arginine responses were increased by progesterone, and antiprogesterone treatment decreased Cyclic Guanosine Monophosphate-induced relaxations. An L-arginine-nitric oxide-Cyclic Guanosine Monophosphate system is present in the uterus and it may regulate relaxation during pregnancy. The inhibitory action of L-arginine and 8-bromo-Cyclic Guanosine Monophosphate was considerably lower during delivery and post partum, indicating that the nitric oxide system may contribute to the maintenance of uterine quiescence during pregnancy, when progesterone levels are elevated, but not during delivery.
-
an l arginine nitric oxide Cyclic Guanosine Monophosphate system exists in the uterus and inhibits contractility during pregnancy
American Journal of Obstetrics and Gynecology, 1994Co-Authors: C Yallampalli, H Izumi, Mary Byamsmith, R E GarfieldAbstract:Abstract OBJECTIVE: Nitric oxide is synthesized from L -arginine and it causes relaxation of smooth muscle by elevating Cyclic Guanosine Monophosphate levels. We hypothesized that an L -arginine–nitric oxide–cGMP system is present in the uterus and modulates contractility. STUDY DESIGN: Isometric tension of the uterus was measured in vitro from pregnant rats in response to various agents that modulate nitric oxide–Cyclic Guanosine Monophosphate production or action. RESULTS: Major findings are as follows: (1) The substrate and a donor of nitric oxide produced uterine relaxation; (2) inhibitors of the nitric oxide–Cyclic Guanosine Monophosphate pathway blocked the relaxation responses; (3) nitric oxide synthase was localized to several uterine cell types; (4) nitric oxide was produced by the uterus during periods when L-arginine was consumed and citrulline levels increased; (5) effects of nitric oxide substrate on relaxation were mimicked by Cyclic Guanosine Monophosphate; (6) nitric oxide–Cyclic Guanosine Monophosphate responses were decreased during delivery; (7) L -arginine responses were increased by progesterone, and antiprogesterone treatment decreased Cyclic Guanosine Monophosphate – induced relaxations. CONCLUSION: An L -arginine–nitric oxide–Cyclic Guanosine Monophosphate system is present in the uterus and it may regulate relaxation during pregnancy. The inhibitory action of L -arginine and 8-bromo-Cyclic Guanosine Monophosphate was considerably lower during delivery and post partum, indicating that the nitric oxide system may contribute to the maintenance of uterine quiescence during pregnancy, when progesterone levels are elevated, but not during delivery. (AM J OBSTET GYNECOL 1993;170:175-85.)
-
An L-arginine–nitric oxide–Cyclic Guanosine Monophosphate system exists in the uterus and inhibits contractility during pregnancy☆☆☆*★★
American Journal of Obstetrics and Gynecology, 1994Co-Authors: C Yallampalli, H Izumi, M Byam-smith, R E GarfieldAbstract:Abstract OBJECTIVE: Nitric oxide is synthesized from L -arginine and it causes relaxation of smooth muscle by elevating Cyclic Guanosine Monophosphate levels. We hypothesized that an L -arginine–nitric oxide–cGMP system is present in the uterus and modulates contractility. STUDY DESIGN: Isometric tension of the uterus was measured in vitro from pregnant rats in response to various agents that modulate nitric oxide–Cyclic Guanosine Monophosphate production or action. RESULTS: Major findings are as follows: (1) The substrate and a donor of nitric oxide produced uterine relaxation; (2) inhibitors of the nitric oxide–Cyclic Guanosine Monophosphate pathway blocked the relaxation responses; (3) nitric oxide synthase was localized to several uterine cell types; (4) nitric oxide was produced by the uterus during periods when L-arginine was consumed and citrulline levels increased; (5) effects of nitric oxide substrate on relaxation were mimicked by Cyclic Guanosine Monophosphate; (6) nitric oxide–Cyclic Guanosine Monophosphate responses were decreased during delivery; (7) L -arginine responses were increased by progesterone, and antiprogesterone treatment decreased Cyclic Guanosine Monophosphate – induced relaxations. CONCLUSION: An L -arginine–nitric oxide–Cyclic Guanosine Monophosphate system is present in the uterus and it may regulate relaxation during pregnancy. The inhibitory action of L -arginine and 8-bromo-Cyclic Guanosine Monophosphate was considerably lower during delivery and post partum, indicating that the nitric oxide system may contribute to the maintenance of uterine quiescence during pregnancy, when progesterone levels are elevated, but not during delivery. (AM J OBSTET GYNECOL 1993;170:175-85.)
R A Ahokas - One of the best experts on this subject based on the ideXlab platform.
-
magnesium sulfate therapy in preeclampsia is associated with increased urinary Cyclic Guanosine Monophosphate excretion
American Journal of Obstetrics and Gynecology, 1992Co-Authors: J R Barton, B M Sibai, R A Ahokas, David W Whybrew, B M MercerAbstract:Abastract OBJECTIVE: Our objective was to determine if maternal urinary Cyclic Guanosine Monophosphate levelsare altered in preeclampsia. STUDY DESIGN : Aliquots from 24-hour urine samples collected from 57 women with preeclampsia and 14 normotensive pregnant women in the third trimester of pregnancy were assayed for urinary Cyclic Guanosine Monophosphate. Urinary Cyclic Guanosine Monophosphate values were expressed per milligram of urinary creatinine to standardize for renal function. RESULTS : There was no difference in gestational age at time of urine collection between the two groups. Urinary Cyclic Guanosine Monophosphate levels (mean ± SD) were similar between normotensive and preeclamptic pregnant women (751 ± 498 vs 632 ± 363 pmol/mg urinary creatinine, respectively, p = 0.12). Preeclamptic women receiving magnesium sulfate had significantly higher levels of urinary Cyclic Guanosine Monophosphate than those not receiving magnesium sulfate (786 ± 360 vs 555 ± 344 pmol/mg urinary creatinine, respectively, p = 0.02). CONCLUSIONS : These preliminary results indicated that Cyclic Guanosine Monophosphate excretion increases in patients with preeclampsia during magnesium sulfate infusion. The vascular smooth muscle relaxation effects of magnesium sulfate may be mediated by directly increasing Cyclic Guanosine Monophosphate production or indirectly through endothelium-derived relaxing factor. (Am J Obstet Gynecol 1992;167:931–4.)
-
Magnesium sulfate therapy in preeclampsia is associated with increased urinary Cyclic Guanosine Monophosphate excretion.
American journal of obstetrics and gynecology, 1992Co-Authors: J R Barton, B M Sibai, R A Ahokas, W D Whybrew, B M MercerAbstract:Our objective was to determine if maternal urinary Cyclic Guanosine Monophosphate levels are altered in preeclampsia. Aliquots from 24-hour urine samples collected from 57 women with preeclampsia and 14 normotensive pregnant women in the third trimester of pregnancy were assayed for urinary Cyclic Guanosine Monophosphate. Urinary Cyclic Guanosine Monophosphate values were expressed per milligram of urinary creatinine to standardize for renal function. There was no difference in gestational age at time of urine collection between the two groups. Urinary Cyclic Guanosine Monophosphate levels (mean +/- SD) were similar between normotensive and preeclamptic pregnant women (751 +/- 498 vs 632 +/- 363 pmol/mg urinary creatinine, respectively, p = 0.12). Preeclamptic women receiving magnesium sulfate had significantly higher levels of urinary Cyclic Guanosine Monophosphate than those not receiving magnesium sulfate (786 +/- 360 vs 555 +/- 344 pmol/mg urinary creatinine, respectively, p = 0.02). These preliminary results indicated that Cyclic Guanosine Monophosphate excretion increases in patients with preeclampsia during magnesium sulfate infusion. The vascular smooth muscle relaxation effects of magnesium sulfate may be mediated by directly increasing Cyclic Guanosine Monophosphate production or indirectly through endothelium-derived relaxing factor.
B M Sibai - One of the best experts on this subject based on the ideXlab platform.
-
magnesium sulfate therapy in preeclampsia is associated with increased urinary Cyclic Guanosine Monophosphate excretion
American Journal of Obstetrics and Gynecology, 1992Co-Authors: J R Barton, B M Sibai, R A Ahokas, David W Whybrew, B M MercerAbstract:Abastract OBJECTIVE: Our objective was to determine if maternal urinary Cyclic Guanosine Monophosphate levelsare altered in preeclampsia. STUDY DESIGN : Aliquots from 24-hour urine samples collected from 57 women with preeclampsia and 14 normotensive pregnant women in the third trimester of pregnancy were assayed for urinary Cyclic Guanosine Monophosphate. Urinary Cyclic Guanosine Monophosphate values were expressed per milligram of urinary creatinine to standardize for renal function. RESULTS : There was no difference in gestational age at time of urine collection between the two groups. Urinary Cyclic Guanosine Monophosphate levels (mean ± SD) were similar between normotensive and preeclamptic pregnant women (751 ± 498 vs 632 ± 363 pmol/mg urinary creatinine, respectively, p = 0.12). Preeclamptic women receiving magnesium sulfate had significantly higher levels of urinary Cyclic Guanosine Monophosphate than those not receiving magnesium sulfate (786 ± 360 vs 555 ± 344 pmol/mg urinary creatinine, respectively, p = 0.02). CONCLUSIONS : These preliminary results indicated that Cyclic Guanosine Monophosphate excretion increases in patients with preeclampsia during magnesium sulfate infusion. The vascular smooth muscle relaxation effects of magnesium sulfate may be mediated by directly increasing Cyclic Guanosine Monophosphate production or indirectly through endothelium-derived relaxing factor. (Am J Obstet Gynecol 1992;167:931–4.)
-
Magnesium sulfate therapy in preeclampsia is associated with increased urinary Cyclic Guanosine Monophosphate excretion.
American journal of obstetrics and gynecology, 1992Co-Authors: J R Barton, B M Sibai, R A Ahokas, W D Whybrew, B M MercerAbstract:Our objective was to determine if maternal urinary Cyclic Guanosine Monophosphate levels are altered in preeclampsia. Aliquots from 24-hour urine samples collected from 57 women with preeclampsia and 14 normotensive pregnant women in the third trimester of pregnancy were assayed for urinary Cyclic Guanosine Monophosphate. Urinary Cyclic Guanosine Monophosphate values were expressed per milligram of urinary creatinine to standardize for renal function. There was no difference in gestational age at time of urine collection between the two groups. Urinary Cyclic Guanosine Monophosphate levels (mean +/- SD) were similar between normotensive and preeclamptic pregnant women (751 +/- 498 vs 632 +/- 363 pmol/mg urinary creatinine, respectively, p = 0.12). Preeclamptic women receiving magnesium sulfate had significantly higher levels of urinary Cyclic Guanosine Monophosphate than those not receiving magnesium sulfate (786 +/- 360 vs 555 +/- 344 pmol/mg urinary creatinine, respectively, p = 0.02). These preliminary results indicated that Cyclic Guanosine Monophosphate excretion increases in patients with preeclampsia during magnesium sulfate infusion. The vascular smooth muscle relaxation effects of magnesium sulfate may be mediated by directly increasing Cyclic Guanosine Monophosphate production or indirectly through endothelium-derived relaxing factor.
